Neuroimaging, genetics and the treatment of nicotine addiction

Behavioural Brain Research

Volumn 193, Issue 2, 2008, Pages 159-169

  Ray, Riju ^a   Loughead, James ^b   Wang, Ze ^c   Detre, John ^c   Yang, Edward ^b   Gur, Ruben ^b   Lerman, Caryn ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b the Center for Neuroimaging in Psychiatry   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

fMRI; Genetics; Neuroimaging; Nicotine; PET; Pharmacogenetics; Smoking

Indexed keywords

GENETIC ANALYSIS; GENETIC ASSOCIATION; GENOMICS; GENOTYPE; HUMAN; NEUROANATOMY; NEUROCHEMISTRY; NEUROIMAGING; PRIORITY JOURNAL; REVIEW; SMOKING CESSATION; TOBACCO DEPENDENCE;

BEHAVIOR, ADDICTIVE; DIAGNOSTIC IMAGING; GENETIC PREDISPOSITION TO DISEASE; GENOMICS; GENOTYPE; HUMANS; POSITRON-EMISSION TOMOGRAPHY; SMOKING; TOBACCO USE DISORDER;

EID: 48949096850     PISSN: 01664328     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbr.2008.05.021     Document Type: Review

References (171)

1. Bergevin A., Girardot D., Bourque M.J., and Trudeau L.E. Presynaptic mu-opioid receptors regulate a late step of the secretory process in rat ventral tegmental area GABAergic neurons. Neuropharmacology 42 8 (2002) 1065-1078
2. Berrettini W., Yuan X., Tozzi F., Song K., Francks C., Chilcoat H., et al. Alpha-5/alpha-3 nicotinic receptor subunit alleles increase risk for heavy smoking. Mol Psychiatry 13 4 (2008) 368-373
3. Berrettini W.H., Wileyto E.P., Epstein L., Restine S., Hawk L., Shields P., et al. Catechol-O-methyltransferase (COMT) gene variants predict response to bupropion therapy for tobacco dependence. Biol Psychiatry 61 1 (2007) 111-118
4. Beuten J., Ma J.Z., Payne T.J., Dupont R.T., Lou X.Y., Crews K.M., et al. Association of specific haplotypes of neurotrophic tyrosine kinase receptor 2 gene (NTRK2) with vulnerability to nicotine dependence in African-Americans and European-Americans. Biol Psychiatry 61 1 (2007) 48-55
5. Beuten J., Ma J.Z., Payne T.J., Dupont R.T., Quezada P., Huang W., et al. Significant association of BDNF haplotypes in European-American male smokers but not in European-American female or African-American smokers. Am J Med Genet B Neuropsychiatr Genet 139 1 (2005) 73-80
6. Beuten J., Payne T.J., Ma J.Z., and Li M.D. Significant association of catechol-O-methyltransferase (COMT) haplotypes with nicotine dependence in male and female smokers of two ethnic populations. Neuropsychopharmacology 31 3 (2006) 675-684
7. Bierut L.J., Madden P.A., Breslau N., Johnson E.O., Hatsukami D., Pomerleau O.F., et al. Novel genes identified in a high-density genome wide association study for nicotine dependence. Hum Mol Genet 16 1 (2007) 24-35
8. Bierut L.J., Rice J.P., Edenberg H.J., Goate A., Foroud T., Cloninger C.R., et al. Family-based study of the association of the dopamine D2 receptor gene (DRD2) with habitual smoking. Am J Med Genet 90 4 (2000) 299-302
9. Borsook D., Becerra L., and Hargreaves R. A role for fMRI in optimizing CNS drug development. Nat Rev Drug Discov 5 5 (2006) 411-424
10. Brody A.L. Functional brain imaging of tobacco use and dependence. J Psychiatr Res 40 5 (2006) 404-418
11. Brody A.L., Mandelkern M.A., Lee G., Smith E., Sadeghi M., Saxena S., et al. Attenuation of cue-induced cigarette craving and anterior cingulate cortex activation in bupropion-treated smokers: a preliminary study. Psychiatry Res 130 3 (2004) 269-281
12. Brody A.L., Mandelkern M.A., London E.D., Childress A.R., Lee G.S., Bota R.G., et al. Brain metabolic changes during cigarette craving. Arch Gen Psychiatry 59 12 (2002) 1162-1172
13. Brody A.L., Mandelkern M.A., London E.D., Olmstead R.E., Farahi J., Scheibal D., et al. Cigarette smoking saturates brain alpha 4 beta 2 nicotinic acetylcholine receptors. Arch Gen Psychiatry 63 8 (2006) 907-915
14. Brody A.L., Mandelkern M.A., Olmstead R.E., Scheibal D., Hahn E., Shiraga S., et al. Gene variants of brain dopamine pathways and smoking-induced dopamine release in the ventral caudate/nucleus accumbens. Arch Gen Psychiatry 63 7 (2006) 808-816
15. Brody A.L., Olmstead R.E., London E.D., Farahi J., Meyer J.H., Grossman P., et al. Smoking-induced ventral striatum dopamine release. Am J Psychiatry 161 7 (2004) 1211-1218
16. Brody A.L., Saxena S., Schwartz J.M., Stoessel P.W., Maidment K., Phelps M.E., et al. FDG-PET predictors of response to behavioral therapy and pharmacotherapy in obsessive compulsive disorder. Psychiatry Res 84 1 (1998) 1-6
17. Brown S.M., and Hariri A.R. Neuroimaging studies of serotonin gene polymorphisms: exploring the interplay of genes, brain, and behavior. Cogn Affect Behav Neurosci 6 1 (2006) 44-52
18. Brown S.M., Peet E., Manuck S.B., Williamson D.E., Dahl R.E., Ferrell R.E., et al. A regulatory variant of the human tryptophan hydroxylase-2 gene biases amygdala reactivity. Mol Psychiatry 10 9 (2005) pp. 884-8, 805
19. Canli T., Congdon E., Gutknecht L., Constable R.T., and Lesch K.P. Amygdala responsiveness is modulated by tryptophan hydroxylase-2 gene variation. J Neural Transm 112 11 (2005) 1479-1485
20. Canli T., Omura K., Haas B.W., Fallgatter A., Constable R.T., and Lesch K.P. Beyond affect: a role for genetic variation of the serotonin transporter in neural activation during a cognitive attention task. Proc Natl Acad Sci USA 102 34 (2005) 12224-12229
21. CDC (2005) Annual Smoking Attributable Mortality, Years of Potential Life Lost, and Productivity Losses-United States, 1997-2001. Volume, 625-628.
22. CDC (2006) Tobacco Use Among Adults-United States, 2005. Volume, 1145-1148.
23. Charpantier E., Barneoud P., Moser P., Besnard F., and Sgard F. Nicotinic acetylcholine subunit mRNA expression in dopaminergic neurons of the rat substantia nigra and ventral tegmental area. Neuroreport 9 13 (1998) 3097-3101
24. Chen C.H., Ridler K., Suckling J., Williams S., Fu C.H., Merlo-Pich E., et al. Brain imaging correlates of depressive symptom severity and predictors of symptom improvement after antidepressant treatment. Biol Psychiatry 62 5 (2007) 407-414
25. Chen J., Nakamura M., Kawamura T., Takahashi T., and Nakahara D. Roles of pedunculopontine tegmental cholinergic receptors in brain stimulation reward in the rat. Psychopharmacology (Berl) 184 3-4 (2006) 514-522
26. Colilla S., Lerman C., Shields P.G., Jepson C., Rukstalis M., Berlin J., et al. Association of catechol-O-methyltransferase with smoking cessation in two independent studies of women. Pharmacogenet Genomics 15 6 (2005) 393-398
27. Comings D.E., Ferry L., Bradshaw-Robinson S., Burchette R., Chiu C., and Muhleman D. The dopamine D2 receptor (DRD2) gene: a genetic risk factor in smoking. Pharmacogenetics 6 1 (1996) 73-79
28. Davenport K.E., Houdi A.A., and Van Loon G.R. Nicotine protects against mu-opioid receptor antagonism by beta-funaltrexamine: evidence for nicotine-induced release of endogenous opioids in brain. Neurosci Lett 113 1 (1990) 40-46
29. David S.P., Brown R.A., Papandonatos G.D., Kahler C.W., Lloyd-Richardson E.E., Munafo M.R., et al. Pharmacogenetic clinical trial of sustained-release bupropion for smoking cessation. Nicotine Tob Res 9 8 (2007) 821-833
30. David S.P., Munafo M.R., Johansen-Berg H., Smith S.M., Rogers R.D., Matthews P.M., et al. Ventral striatum/nucleus accumbens activation to smoking-related pictorial cues in smokers and nonsmokers: a functional magnetic resonance imaging study. Biol Psychiatry 58 6 (2005) 488-494
31. David S.P., Munafo M.R., Murphy M.F., Proctor M., Walton R.T., and Johnstone E.C. Genetic variation in the dopamine D4 receptor (DRD4) gene and smoking cessation: follow-up of a randomised clinical trial of transdermal nicotine patch. Pharmacogenom J (2007)
32. David S.P., Strong D.R., Munafo M.R., Brown R.A., Lloyd-Richardson E.E., Wileyto P.E., et al. Bupropion efficacy for smoking cessation is influenced by the DRD2 Taq1A polymorphism: Analysis of pooled data from two clinical trials. Nicotine Tob Res 9 12 (2007) 1251-1257
33. deCharms R.C. Reading and controlling human brain activation using real-time functional magnetic resonance imaging. Trends Cogn Sci 11 11 (2007) 473-481
34. Detre J.A., Leigh J.S., Williams D.S., and Koretsky A.P. Perfusion imaging. Magn Reson Med 23 1 (1992) 37-45
35. Due D.L., Huettel S.A., Hall W.G., and Rubin D.C. Activation in mesolimbic and visuospatial neural circuits elicited by smoking cues: evidence from functional magnetic resonance imaging. Am J Psychiatry 159 6 (2002) 954-960
36. Egan M.F., Goldberg T.E., Kolachana B.S., Callicott J.H., Mazzanti C.M., Straub R.E., et al. Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proc Natl Acad Sci USA 98 12 (2001) 6917-6922
37. Ernst M., Matochik J.A., Heishman S.J., Van Horn J.D., Jons P.H., Henningfield J.E., et al. Effect of nicotine on brain activation during performance of a working memory task. Proc Natl Acad Sci USA 98 8 (2001) 4728-4733
38. Ersche K.D., Fletcher P.C., Roiser J.P., Fryer T.D., London M., Robbins T.W., et al. Differences in orbitofrontal activation during decision-making between methadone-maintained opiate users, heroin users and healthy volunteers. Psychopharmacology (Berl) 188 3 (2006) 364-373
39. Ettinger U., Kumari V., Collier D.A., Powell J., Luzi S., Michel T.M., et al. Catechol-O-methyltransferase (COMT) Val(158)Met genotype is associated with BOLD response as a function of task characteristic. Neuropsychopharmacology (2008)
40. Feng Y., Niu T., Xing H., Xu X., Chen C., Peng S., et al. A common haplotype of the nicotine acetylcholine receptor alpha 4 subunit gene is associated with vulnerability to nicotine addiction in men. Am J Hum Genet 75 1 (2004) 112-121
41. Forbes E.E., Brown S.M., Kimak M., Ferrell R.E., Manuck S.B., and Hariri A.R. Genetic variation in components of dopamine neurotransmission impacts ventral striatal reactivity associated with impulsivity. Mol Psychiatry (2007)
42. Franklin T.R., Wang Z., Wang J., Sciortino N., Harper D., Li Y., et al. Limbic activation to cigarette smoking cues independent of nicotine withdrawal: a perfusion fMRI study. Neuropsychopharmacology 32 11 (2007) 2301-2309
43. Freire M.T., Marques F.Z., Hutz M.H., and Bau C.H. Polymorphisms in the DBH and DRD2 gene regions and smoking behavior. Eur Arch Psychiatry Clin Neurosci 256 2 (2006) 93-97
44. Fu C.H., Williams S.C., Cleare A.J., Brammer M.J., Walsh N.D., Kim J., et al. Attenuation of the neural response to sad faces in major depression by antidepressant treatment: a prospective, event-related functional magnetic resonance imaging study. Arch Gen Psychiatry 61 9 (2004) 877-889
45. Furmark T., Tillfors M., Garpenstrand H., Marteinsdottir I., Langstrom B., Oreland L., et al. Serotonin transporter polymorphism related to amygdala excitability and symptom severity in patients with social phobia. Neurosci Lett 362 3 (2004) 189-192
46. Greenbaum L., Kanyas K., Karni O., Merbl Y., Olender T., Horowitz A., et al. Why do young women smoke? I. Direct and interactive effects of environment, psychological characteristics and nicotinic cholinergic receptor genes. Mol Psychiatry 11 3 (2006) pp. 312-22, 223
47. Grenhoff J., Aston-Jones G., and Svensson T.H. Nicotinic effects on the firing pattern of midbrain dopamine neurons. Acta Physiol Scand 128 3 (1986) 351-358
48. Gu D.F., Hinks L.J., Morton N.E., and Day I.N. The use of long PCR to confirm three common alleles at the CYP2A6 locus and the relationship between genotype and smoking habit. Ann Hum Genet 64 Pt 5 (2000) 383-390
49. Hariri A.R., Drabant E.M., Munoz K.E., Kolachana B.S., Mattay V.S., Egan M.F., et al. A susceptibility gene for affective disorders and the response of the human amygdala. Arch Gen Psychiatry 62 2 (2005) 146-152
50. Hariri A.R., Mattay V.S., Tessitore A., Kolachana B., Fera F., Goldman D., et al. Serotonin transporter genetic variation and the response of the human amygdala. Science 297 5580 (2002) 400-403
51. Heils A., Teufel A., Petri S., Stober G., Riederer P., Bengel D., et al. Allelic variation of human serotonin transporter gene expression. J Neurochem 66 6 (1996) 2621-2624
52. Heinz A., Braus D.F., Smolka M.N., Wrase J., Puls I., Hermann D., et al. Amygdala-prefrontal coupling depends on a genetic variation of the serotonin transporter. Nat Neurosci 8 1 (2005) 20-21
53. Heitjan D.F., Guo M., Ray R., Wileyto E.P., Epstein L.H., and Lerman C. Identification of pharmacogenetic markers in smoking cessation therapy. Am J Med Genet B Neuropsychiatr Genet (2007)
54. Hermann D., Smolka M.N., Wrase J., Klein S., Nikitopoulos J., Georgi A., et al. Blockade of cue-induced brain activation of abstinent alcoholics by a single administration of amisulpride as measured with fMRI. Alcohol Clin Exp Res 30 8 (2006) 1349-1354
55. Ho B.C., Wassink T.H., O'Leary D.S., Sheffield V.C., and Andreasen N.C. Catechol-O-methyl transferase Val158Met gene polymorphism in schizophrenia: working memory, frontal lobe MRI morphology and frontal cerebral blood flow. Mol Psychiatry 10 3 (2005) pp. 229, 287-98
56. Huang W., Payne T.J., Ma J.Z., Beuten J., Dupont R.T., Inohara N., et al. Significant Association of ANKK1 and Detection of a Functional Polymorphism with Nicotine Dependence in an African-American Sample. Neuropsychopharmacology (2008)
57. Huang W., Payne T.J., Ma J.Z., and Li M.D. A functional polymorphism, rs6280, in DRD3 is significantly associated with nicotine dependence in European-American smokers. Am J Med Genet B Neuropsychiatr Genet (2008)
58. Hutchison K.E., Allen D.L., Filbey F.M., Jepson C., Lerman C., Benowitz N.L., et al. CHRNA4 and tobacco dependence: from gene regulation to treatment outcome. Arch Gen Psychiatry 64 9 (2007) 1078-1086
59. Hutchison K.E., LaChance H., Niaura R., Bryan A., and Smolen A. The DRD4 VNTR polymorphism influences reactivity to smoking cues. J Abnorm Psychol 111 1 (2002) 134-143
60. Jacobsen L.K., Mencl W.E., Constable R.T., Westerveld M., and Pugh K.R. Impact of smoking abstinence on working memory neurocircuitry in adolescent daily tobacco smokers. Psychopharmacology (Berl) 193 4 (2007) 557-566
61. Jacobsen L.K., Pugh K.R., Mencl W.E., and Gelernter J. C957T polymorphism of the dopamine D2 receptor gene modulates the effect of nicotine on working memory performance and cortical processing efficiency. Psychopharmacology (Berl) 188 4 (2006) 530-540
62. Jacobsen L.K., Slotkin T.A., Westerveld M., Mencl W.E., and Pugh K.R. Visuospatial memory deficits emerging during nicotine withdrawal in adolescents with prenatal exposure to active maternal smoking. Neuropsychopharmacology 31 7 (2006) 1550-1561
63. Johnstone E.C., Elliot K.M., David S.P., Murphy M.F., Walton R.T., and Munafo M.R. Association of COMT Val108/158Met genotype with smoking cessation in a nicotine replacement therapy randomized trial. Cancer Epidemiol Biomarkers Prev 16 6 (2007) 1065-1069
64. Johnstone E.C., Yudkin P.L., Hey K., Roberts S.J., Welch S.J., Murphy M.F., et al. Genetic variation in dopaminergic pathways and short-term effectiveness of the nicotine patch. Pharmacogenetics 14 2 (2004) 83-90
65. Jones I.W., and Wonnacott S. Precise localization of alpha7 nicotinic acetylcholine receptors on glutamatergic axon terminals in the rat ventral tegmental area. J Neurosci 24 50 (2004) 11244-11252
66. Kalivas P.W. Neurotransmitter regulation of dopamine neurons in the ventral tegmental area. Brain Res Brain Res Rev 18 1 (1993) 75-113
67. Kennedy S.H., Konarski J.Z., Segal Z.V., Lau M.A., Bieling P.J., McIntyre R.S., et al. Differences in brain glucose metabolism between responders to CBT and venlafaxine in a 16-week randomized controlled trial. Am J Psychiatry 164 5 (2007) 778-788
68. Killen J.D., and Fortmann S.P. Craving is associated with smoking relapse: findings from three prospective studies. Exp Clin Psychopharmacol 5 2 (1997) 137-142
69. Klink R., de Kerchove d'Exaerde A., Zoli M., and Changeux J.P. Molecular and physiological diversity of nicotinic acetylcholine receptors in the midbrain dopaminergic nuclei. J Neurosci 21 5 (2001) 1452-1463
70. Kosten T.R., Scanley B.E., Tucker K.A., Oliveto A., Prince C., Sinha R., et al. Cue-induced brain activity changes and relapse in cocaine-dependent patients. Neuropsychopharmacology 31 3 (2006) 644-650
71. Kubota T., Nakajima-Taniguchi C., Fukuda T., Funamoto M., Maeda M., Tange E., et al. CYP2A6 polymorphisms are associated with nicotine dependence and influence withdrawal symptoms in smoking cessation. Pharmacogenomics J 6 2 (2006) 115-119
72. Kumari V., Gray J.A., ffytche D.H., Mitterschiffthaler M.T., Das M., Zachariah E., et al. Cognitive effects of nicotine in humans: an fMRI study. Neuroimage 19 3 (2003) 1002-1013
73. Lagreze H.L., and Levine R.L. Quantitative positron emission tomography and single photon emission computed tomography measurements of human cerebral blood flow. Am J Physiol Imaging 2 4 (1987) 208-215
74. Lang U.E., Sander T., Lohoff F.W., Hellweg R., Bajbouj M., Winterer G., et al. Association of the met66 allele of brain-derived neurotrophic factor (BDNF) with smoking. Psychopharmacology (Berl) 190 4 (2007) 433-439
75. Langenecker S.A., Kennedy S.E., Guidotti L.M., Briceno E.M., Own L.S., Hooven T., et al. Frontal and limbic activation during inhibitory control predicts treatment response in major depressive disorder. Biol Psychiatry 62 11 (2007) 1272-1280
76. Lawrence N.S., Ross T.J., and Stein E.A. Cognitive mechanisms of nicotine on visual attention. Neuron 36 3 (2002) 539-548
77. Lee A.M., Jepson C., Hoffmann E., Epstein L., Hawk L.W., Lerman C., et al. CYP2B6 genotype alters abstinence rates in a bupropion smoking cessation trial. Biol Psychiatry 62 6 (2007) 635-641
78. Lee J.H., Lim Y., Wiederhold B.K., and Graham S.J. A functional magnetic resonance imaging (FMRI) study of cue-induced smoking craving in virtual environments. Appl Psychophysiol Biofeedback 30 3 (2005) 195-204
79. Lerman C., Caporaso N.E., Audrain J., Main D., Bowman E.D., Lockshin B., et al. Evidence suggesting the role of specific genetic factors in cigarette smoking. Health Psychol 18 1 (1999) 14-20
80. Lerman C., Jepson C., Wileyto E.P., Epstein L.H., Rukstalis M., Patterson F., et al. Role of functional genetic variation in the dopamine D2 receptor (DRD2) in response to bupropion and nicotine replacement therapy for tobacco dependence: results of two randomized clinical trials. Neuropsychopharmacology 31 1 (2006) 231-242
81. Lerman C., Lesage M.G., Perkins K.A., O'Malley S., Siegel S.J., Benowitz N.L., et al. Translational research in medication development for nicotine dependence. Nat Rev Drug Discov 6 9 (2007) 746-762
82. Lerman C., Shields P.G., Wileyto E.P., Audrain J., Hawk Jr. L.H., Pinto A., et al. Effects of dopamine transporter and receptor polymorphisms on smoking cessation in a bupropion clinical trial. Health Psychol 22 5 (2003) 541-548
83. Lerman C., Tyndale R., Patterson F., Wileyto E.P., Shields P.G., Pinto A., et al. Nicotine metabolite ratio predicts efficacy of transdermal nicotine for smoking cessation. Clin Pharmacol Ther 79 6 (2006) 600-608
84. Lerman C., Wileyto E.P., Patterson F., Rukstalis M., Audrain-McGovern J., Restine S., et al. The functional mu opioid receptor (OPRM1) Asn40Asp variant predicts short-term response to nicotine replacement therapy in a clinical trial. Pharmacogenomics J 4 3 (2004) 184-192
85. Lerman C.E., Schnoll R.A., and Munafo M.R. Genetics and smoking cessation improving outcomes in smokers at risk. Am J Prev Med 33 6 Suppl. (2007) S398-S405
86. Li M.D. The genetics of nicotine dependence. Curr Psychiatry Rep 8 2 (2006) 158-164
87. Li M.D., Beuten J., Ma J.Z., Payne T.J., Lou X.Y., Garcia V., et al. Ethnic- and gender-specific association of the nicotinic acetylcholine receptor alpha4 subunit gene (CHRNA4) with nicotine dependence. Hum Mol Genet 14 9 (2005) 1211-1219
88. Li M.D., Payne T.J., Ma J.Z., Lou X.Y., Zhang D., Dupont R.T., et al. A genomewide search finds major susceptibility loci for nicotine dependence on chromosome 10 in African Americans. Am J Hum Genet 79 4 (2006) 745-751
89. Lou X.Y., Ma J.Z., Payne T.J., Beuten J., Crew K.M., and Li M.D. Gene-based analysis suggests association of the nicotinic acetylcholine receptor beta1 subunit (CHRNB1) and M1 muscarinic acetylcholine receptor (CHRM1) with vulnerability for nicotine dependence. Hum Genet 120 3 (2006) 381-389
90. Lueders K.K., Hu S., McHugh L., Myakishev M.V., Sirota L.A., and Hamer D.H. Genetic and functional analysis of single nucleotide polymorphisms in the beta2-neuronal nicotinic acetylcholine receptor gene (CHRNB2). Nicotine Tob Res 4 1 (2002) 115-125
91. Ma J.Z., Beuten J., Payne T.J., Dupont R.T., Elston R.C., and Li M.D. Haplotype analysis indicates an association between the DOPA decarboxylase (DDC) gene and nicotine dependence. Hum Mol Genet 14 12 (2005) 1691-1698
92. Malaiyandi V., Lerman C., Benowitz N.L., Jepson C., Patterson F., and Tyndale R.F. Impact of CYP2A6 genotype on pretreatment smoking behaviour and nicotine levels from and usage of nicotine replacement therapy. Mol Psychiatry 11 4 (2006) 400-409
93. Malaiyandi V., Sellers E.M., and Tyndale R.F. Implications of CYP2A6 genetic variation for smoking behaviors and nicotine dependence. Clin Pharmacol Ther 77 3 (2005) 145-158
94. Mamede M., Ishizu K., Ueda M., Mukai T., Iida Y., Kawashima H., et al. Temporal change in human nicotinic acetylcholine receptor after smoking cessation: 5IA SPECT study. J Nucl Med 48 11 (2007) 1829-1835
95. Mansvelder H.D., De Rover M., McGehee D.S., and Brussaard A.B. Cholinergic modulation of dopaminergic reward areas: upstream and downstream targets of nicotine addiction. Eur J Pharmacol 480 1-3 (2003) 117-123
96. Mansvelder H.D., Keath J.R., and McGehee D.S. Synaptic mechanisms underlie nicotine-induced excitability of brain reward areas. Neuron 33 6 (2002) 905-919
97. Mattay V.S., Goldberg T.E., Fera F., Hariri A.R., Tessitore A., Egan M.F., et al. Catechol-O-methyltransferase val158-met genotype and individual variation in the brain response to amphetamine. Proc Natl Acad Sci USA 100 10 (2003) 6186-6191
98. McBride D., Barrett S.P., Kelly J.T., Aw A., and Dagher A. Effects of expectancy and abstinence on the neural response to smoking cues in cigarette smokers: an fMRI study. Neuropsychopharmacology 31 12 (2006) 2728-2738
99. McClernon F.J., and Gilbert D.G. Human functional neuroimaging in nicotine and tobacco research: basics, background, and beyond. Nicotine Tob Res 6 6 (2004) 941-959
100. McClernon F.J., Hiott F.B., Huettel S.A., and Rose J.E. Abstinence-induced changes in self-report craving correlate with event-related FMRI responses to smoking cues. Neuropsychopharmacology 30 10 (2005) 1940-1947
101. McClernon F.J., Hutchison K.E., Rose J.E., and Kozink R.V. DRD4 VNTR polymorphism is associated with transient fMRI-BOLD responses to smoking cues. Psychopharmacology (Berl) 194 4 (2007) 433-441
102. McClernon F.J., Kozink R.V., and Rose J.E. Individual differences in nicotine dependence, withdrawal symptoms, and sex predict transient fMRI-BOLD responses to smoking cues. Neuropsychopharmacology (2007)
103. McClure E.B., Adler A., Monk C.S., Cameron J., Smith S., Nelson E.E., et al. fMRI predictors of treatment outcome in pediatric anxiety disorders. Psychopharmacology (Berl) 191 1 (2007) 97-105
104. McKinney E.F., Walton R.T., Yudkin P., Fuller A., Haldar N.A., Mant D., et al. Association between polymorphisms in dopamine metabolic enzymes and tobacco consumption in smokers. Pharmacogenetics 10 6 (2000) 483-491
105. Meyer-Lindenberg A., Kohn P.D., Kolachana B., Kippenhan S., McInerney-Leo A., Nussbaum R., et al. Midbrain dopamine and prefrontal function in humans: interaction and modulation by COMT genotype. Nat Neurosci 8 5 (2005) 594-596
106. Meyer-Lindenberg A., Nicodemus K.K., Egan M.F., Callicott J.H., Mattay V., and Weinberger D.R. False positives in imaging genetics. Neuroimage 40 2 (2008) 655-661
107. Mifsud J.C., Hernandez L., and Hoebel B.G. Nicotine infused into the nucleus accumbens increases synaptic dopamine as measured by in vivo microdialysis. Brain Res 478 2 (1989) 365-367
108. Montgomery A.J., Lingford-Hughes A.R., Egerton A., Nutt D.J., and Grasby P.M. The effect of nicotine on striatal dopamine release in man: A [11C]raclopride PET study. Synapse 61 8 (2007) 637-645
109. Munafo M., Clark T., Johnstone E., Murphy M., and Walton R. The genetic basis for smoking behavior: a systematic review and meta-analysis. Nicotine Tob Res 6 4 (2004) 583-597
110. Munafo M.R., Johnstone E.C., Guo B., Murphy M.F., and Aveyard P. Association of COMT Val108/158Met genotype with smoking cessation. Pharmacogenet Genomics 18 2 (2008) 121-128
111. Neville M.J., Johnstone E.C., and Walton R.T. Identification and characterization of ANKK1: a novel kinase gene closely linked to DRD2 on chromosome band 11q23.1. Hum Mutat 23 6 (2004) 540-545
112. Nisell M., Nomikos G.G., and Svensson T.H. Systemic nicotine-induced dopamine release in the rat nucleus accumbens is regulated by nicotinic receptors in the ventral tegmental area. Synapse 16 1 (1994) 36-44
113. Nussbaum J., Xu Q., Payne T.J., Ma J.Z., Huang W., Gelernter J., et al. Significant association of the neurexin 1 gene (NRXN1) with nicotine dependence in European and African American smokers. Hum Mol Genet (2008)
114. Ogawa S., Lee T.M., Kay A.R., and Tank D.W. Brain magnetic resonance imaging with contrast dependent on blood oxygenation. Proc Natl Acad Sci USA 87 24 (1990) 9868-9872
115. Okuyemi K.S., Powell J.N., Savage C.R., Hall S.B., Nollen N., Holsen L.M., et al. Enhanced cue-elicited brain activation in African American compared with Caucasian smokers: an fMRI study. Addict Biol 11 1 (2006) 97-106
116. Patterson F., Schnoll R., Wileyto E., Pinto A., Epstein L., Shields P., et al. Toward personalized therapy for smoking cessation: a randomized placebo-controlled trial of Bupropion. Clin Pharmacol Ther (2008)
117. Paulus M.P., Feinstein J.S., Castillo G., Simmons A.N., and Stein M.B. Dose-dependent decrease of activation in bilateral amygdala and insula by lorazepam during emotion processing. Arch Gen Psychiatry 62 3 (2005) 282-288
118. Pezawas L., Meyer-Lindenberg A., Drabant E.M., Verchinski B.A., Munoz K.E., Kolachana B.S., et al. 5-HTTLPR polymorphism impacts human cingulate-amygdala interactions: a genetic susceptibility mechanism for depression. Nat Neurosci 8 6 (2005) 828-834
119. Raichle M.E., Welch M.J., Grubb Jr. R.L., Larson K.B., Laux B.E., and Ter-Pogossian M.M. Regional cerebral oxygen utilization with positron emission tomography. Trans Am Neurol Assoc 104 (1979) 154-156
120. Rao H., Gillihan S.J., Wang J., Korczykowski M., Sankoorikal G.M., Kaercher K.A., et al. Genetic variation in serotonin transporter alters resting brain function in healthy individuals. Biol Psychiatry 62 6 (2007) 600-606
121. Ray R., Jepson C., Patterson F., Strasser A., Rukstalis M., Perkins K., et al. Association of OPRM1 A118G variant with the relative reinforcing value of nicotine. Psychopharmacology (Berl) 188 3 (2006) 355-363
122. Reichlin M. The challenges of neuroethics. Funct Neurol 22 4 (2007) 235-242
123. Rose J.E., Behm F.M., Salley A.N., Bates J.E., Coleman R.E., Hawk T.C., et al. Regional brain activity correlates of nicotine dependence. Neuropsychopharmacology 32 12 (2007) 2441-2452
124. Sabol S.Z., Nelson M.L., Fisher C., Gunzerath L., Brody C.L., Hu S., et al. A genetic association for cigarette smoking behavior. Health Psychol 18 1 (1999) 7-13
125. Saccone S.F., Hinrichs A.L., Saccone N.L., Chase G.A., Konvicka K., Madden P.A., et al. Cholinergic nicotinic receptor genes implicated in a nicotine dependence association study targeting 348 candidate genes with 3713 SNPs. Hum Mol Genet 16 1 (2007) 36-49
126. Saxena S., Brody A.L., Ho M.L., Alborzian S., Maidment K.M., Zohrabi N., et al. Differential cerebral metabolic changes with paroxetine treatment of obsessive-compulsive disorder vs major depression. Arch Gen Psychiatry 59 3 (2002) 250-261
127. Saxena S., Brody A.L., Maidment K.M., Dunkin J.J., Colgan M., Alborzian S., et al. Localized orbitofrontal and subcortical metabolic changes and predictors of response to paroxetine treatment in obsessive-compulsive disorder. Neuropsychopharmacology 21 6 (1999) 683-693
128. Schnoll R.A., and Lerman C. Current and emerging pharmacotherapies for treating tobacco dependence. Expert Opin Emerg Drugs 11 3 (2006) 429-444
129. Scott D.J., Domino E.F., Heitzeg M.M., Koeppe R.A., Ni L., Guthrie S., et al. Smoking modulation of mu-opioid and dopamine D2 receptor-mediated neurotransmission in humans. Neuropsychopharmacology 32 2 (2007) 450-457
130. Sesack S.R., and Pickel V.M. Prefrontal cortical efferents in the rat synapse on unlabeled neuronal targets of catecholamine terminals in the nucleus accumbens septi and on dopamine neurons in the ventral tegmental area. J Comp Neurol 320 2 (1992) 145-160
131. Shields A.E., and Lerman C. Anticipating clinical integration of pharmacogenetic treatment strategies for addiction: are primary care physicians ready?. Clin Pharmacol Ther 83 4 (2008) 635-639
132. Shields P.G., Lerman C., Audrain J., Bowman E.D., Main D., Boyd N.R., et al. Dopamine D4 receptors and the risk of cigarette smoking in African-Americans and Caucasians. Cancer Epidemiol Biomarkers Prev 7 6 (1998) 453-458
133. Silverman M.A., Neale M.C., Sullivan P.F., Harris-Kerr C., Wormley B., Sadek H., et al. Haplotypes of four novel single nucleotide polymorphisms in the nicotinic acetylcholine receptor beta2-subunit (CHRNB2) gene show no association with smoking initiation or nicotine dependence. Am J Med Genet 96 5 (2000) 646-653
134. Smolka M.N., Buhler M., Klein S., Zimmermann U., Mann K., Heinz A., et al. Severity of nicotine dependence modulates cue-induced brain activity in regions involved in motor preparation and imagery. Psychopharmacology (Berl) 184 3-4 (2006) 577-588
135. Spitz M.R., Shi H., Yang F., Hudmon K.S., Jiang H., Chamberlain R.M., et al. Case-control study of the D2 dopamine receptor gene and smoking status in lung cancer patients. J Natl Cancer Inst 90 5 (1998) 358-363
136. Staley J.K., Krishnan-Sarin S., Cosgrove K.P., Krantzler E., Frohlich E., Perry E., et al. Human tobacco smokers in early abstinence have higher levels of beta2* nicotinic acetylcholine receptors than nonsmokers. J Neurosci 26 34 (2006) 8707-8714
137. Stapleton J.A., Sutherland G., and O'Gara C. Association between dopamine transporter genotypes and smoking cessation: a meta-analysis. Addict Biol 12 2 (2007) 221-226
138. Stapleton J.M., Gilson S.F., Wong D.F., Villemagne V.L., Dannals R.F., Grayson R.F., et al. Intravenous nicotine reduces cerebral glucose metabolism: a preliminary study. Neuropsychopharmacology 28 4 (2003) 765-772
139. Stein E.A., Pankiewicz J., Harsch H.H., Cho J.K., Fuller S.A., Hoffmann R.G., et al. Nicotine-induced limbic cortical activation in the human brain: a functional MRI study. Am J Psychiatry 155 8 (1998) 1009-1015
140. Sullivan P.F., and Kendler K.S. The genetic epidemiology of smoking. Nicotine Tob Res 1 Suppl 2 (1999) S51-S57 [discussion S69-70]
141. Sun D., Ma J.Z., Payne T.J., and Li M.D. Beta-arrestins 1 and 2 are associated with nicotine dependence in European American smokers. Mol Psychiatry 13 4 (2008) 398-406
142. Swan G.E., Jack L.M., Valdes A.M., Ring H.Z., Ton C.C., Curry S.J., et al. Joint effect of dopaminergic genes on likelihood of smoking following treatment with bupropion SR. Health Psychol 26 3 (2007) 361-368
143. Takahashi H., Fujimura Y., Hayashi M., Takano H., Kato M., Okubo Y., et al. Enhanced dopamine release by nicotine in cigarette smokers: a double-blind, randomized, placebo-controlled pilot study. Int J Neuropsychopharmacol (2007) 1-5
144. Tanabe J., Crowley T., Hutchison K., Miller D., Johnson G., Du Y.P., et al. Ventral striatal blood flow is altered by acute nicotine but not withdrawal from nicotine. Neuropsychopharmacology 33 3 (2008) 627-633
145. Tanabe J., Tregellas J.R., Martin L.F., and Freedman R. Effects of nicotine on hippocampal and cingulate activity during smooth pursuit eye movement in schizophrenia. Biol Psychiatry 59 8 (2006) 754-761
146. Thorgeirsson T.E., Geller F., Sulem P., Rafnar T., Wiste A., Magnusson K.P., et al. A variant associated with nicotine dependence, lung cancer and peripheral arterial disease. Nature 452 7187 (2008) 638-642
147. Timberlake D.S., Haberstick B.C., Lessem J.M., Smolen A., Ehringer M., Hewitt J.K., et al. An association between the DAT1 polymorphism and smoking behavior in young adults from the National Longitudinal Study of Adolescent Health. Health Psychol 25 2 (2006) 190-197
148. Tochigi M., Suzuki K., Kato C., Otowa T., Hibino H., Umekage T., et al. Association study of monoamine oxidase and catechol-O-methyltransferase genes with smoking behavior. Pharmacogenet Genomics 17 10 (2007) 867-872
149. Ton T.G., Rossing M.A., Bowen D.J., Srinouanprachan S., Wicklund K., and Farin F.M. Genetic polymorphisms in dopamine-related genes and smoking cessation in women: a prospective cohort study. Behav Brain Funct 3 (2007) 22
150. Uhl G.R., Liu Q.R., Drgon T., Johnson C., Walther D., Rose J., et al. Molecular genetics of successful smoking cessation: convergent genome-wide association results. Arch Gen Psychiatry 65 6 (2008) 683-693
151. Uhl G.R., Liu Q.R., Drgon T., Johnson C., Walther D., and Rose J.E. Molecular genetics of nicotine dependence and abstinence: whole genome association using 520,000 SNPs. BMC Genet 8 (2007) 10
152. Vandenbergh D.J., Bennett C.J., Grant M.D., Strasser A.A., O'Connor R., Stauffer R.L., et al. Smoking status and the human dopamine transporter variable number of tandem repeats (VNTR) polymorphism: failure to replicate and finding that never-smokers may be different. Nicotine Tob Res 4 3 (2002) 333-340
153. Vandenbergh D.J., O'Connor R.J., Grant M.D., Jefferson A.L., Vogler G.P., Strasser A.A., et al. Dopamine receptor genes (DRD2, DRD3 and DRD4) and gene-gene interactions associated with smoking-related behaviors. Addict Biol 12 1 (2007) 106-116
154. Wagner Jr. H.N., Burns H.D., Dannals R.F., Wong D.F., Langstrom B., Duelfer T., et al. Assessment of dopamine receptor densities in the human brain with carbon-11-labeled N-methylspiperone. Ann Neurol 15 Suppl. (1984) S79-S84
155. Walaas I., and Fonnum F. Biochemical evidence for gamma-aminobutyrate containing fibres from the nucleus accumbens to the substantia nigra and ventral tegmental area in the rat. Neuroscience 5 1 (1980) 63-72
156. Wang Z., Faith M., Kerrin K., Tang K., Wileyto E.P., Patterson F., et al. Neural substrates of abstinence-induced cigarette cravings in chronic smokers. J Neurosci 27 (2007) 14030-14040
157. Wang Z, Ray, R, Faith, M, Tang, K, Wileyto, EP, Detre, JA, et al. Nicotine abstinence-induced cerebral blood flow changes by genotype. Neurosci Lett; in press.
158. Weiskopf N., Sitaram R., Josephs O., Veit R., Scharnowski F., Goebel R., et al. Real-time functional magnetic resonance imaging: methods and applications. Magn Reson Imaging 25 6 (2007) 989-1003
159. Weizman A., and Weizman R. Serotonin transporter polymorphism and response to SSRIs in major depression and relevance to anxiety disorders and substance abuse. Pharmacogenomics 1 3 (2000) 335-341
160. Wewers M.E., Dhatt R.K., Snively T.A., and Tejwani G.A. The effect of chronic administration of nicotine on antinociception, opioid receptor binding and met-enkelphalin levels in rats. Brain Res 822 1-2 (1999) 107-113
161. Whiting P., and Lindstrom J. Pharmacological properties of immuno-isolated neuronal nicotinic receptors. J Neurosci 6 10 (1986) 3061-3069
162. Winterer G., Musso F., Vucurevic G., Stoeter P., Konrad A., Seker B., et al. COMT genotype predicts BOLD signal and noise characteristics in prefrontal circuits. Neuroimage 32 4 (2006) 1722-1732
163. Xian H., Scherrer J.F., Madden P.A., Lyons M.J., Tsuang M., True W.R., et al. The heritability of failed smoking cessation and nicotine withdrawal in twins who smoked and attempted to quit. Nicotine Tob Res 5 2 (2003) 245-254
164. Xu J., Mendrek A., Cohen M.S., Monterosso J., Rodriguez P., Simon S.L., et al. Brain activity in cigarette smokers performing a working memory task: effect of smoking abstinence. Biol Psychiatry 58 2 (2005) 143-150
165. Xu J., Mendrek A., Cohen M.S., Monterosso J., Simon S., Brody A.L., et al. Effects of acute smoking on brain activity vary with abstinence in smokers performing the N-Back task: a preliminary study. Psychiatry Res 148 2-3 (2006) 103-109
166. Yeomans J., and Baptista M. Both nicotinic and muscarinic receptors in ventral tegmental area contribute to brain-stimulation reward. Pharmacol Biochem Behav 57 4 (1997) 915-921
167. Yeomans J., Forster G., and Blaha C. M5 muscarinic receptors are needed for slow activation of dopamine neurons and for rewarding brain stimulation. Life Sci 68 22-23 (2001) 2449-2456
168. Zhang H., Ye Y., Wang X., Gelernter J., Ma J.Z., and Li M.D. DOPA decarboxylase gene is associated with nicotine dependence. Pharmacogenomics 7 8 (2006) 1159-1166
169. Zhang Y., Wang D., Johnson A.D., Papp A.C., and Sadee W. Allelic expression imbalance of human mu opioid receptor (OPRM1) caused by variant A118G. J Biol Chem 280 38 (2005) 32618-32624
170. Zubieta J., Lombardi U., Minoshima S., Guthrie S., Ni L., Ohl L.E., et al. Regional cerebral blood flow effects of nicotine in overnight abstinent smokers. Biol Psychiatry 49 11 (2001) 906-913
171. Zubieta J.K., Heitzeg M.M., Xu Y., Koeppe R.A., Ni L., Guthrie S., et al. Regional cerebral blood flow responses to smoking in tobacco smokers after overnight abstinence. Am J Psychiatry 162 3 (2005) 567-577